Ann Dendoncker

Part of Verizon Communications, Inc., MCI BeLux is a telecommunications and internet service provider. The company is based in Diegem, Belgium.

CropDesign NV develops traits for cereal crops. It delivers agronomic traits for the global commercial seed markets. The firm focuses on enhancing grain yield in crops such as corn and rice, and increasing biomass of energy crops. Its platform, TraitMill, lows evaluating the effect of genes on the performance of plants under different growing conditions, including drought and low nutrient stress. The company was founded in 1998 and is headquartered in Zwijnaarde, Blgium.

Ogeda SA discovers and develops small molecule drugs. It develops NK3 antagonists for the treatment of hormone-dependent pathologies in the field of Women's Health. The company was founded in 1994 and is headquartered in Gosselies, Spain.

Suez Lyonnaise des Eaux Finance SA provides financial services to raise funds for the business operations. The company is headquartered in Paris, France.

Intrexon ActoBiotics NV manufactures biopharmaceutical products. It focuses on the development and commercialization of a new generation of biological drugs. The company represents a novel concept for oral administration of therapeutic proteins, and is designed to be safer and more effective than injectable biopharmaceuticals. Intrexon Actobioticswas founded by Mark Vaeck, Emil Pot and Bernard Coulie in June 2006 and is headquartered in Zwijnaarde, Belgium.

Bio-Incubator Leuven is a dynamic and innovative environment that provides lab space and support to R&D-intensive life sciences companies. The private company offers customizable modules that can be modified to meet the specific requirements of each client. The company is based in Leuven, Belgium. Leuven's knowledge institutes, including KU Leuven, University Hospitals Leuven, VIB, and IMEC, generate a huge outflow of knowledge that entails a myriad of innovative ideas for new and existing companies. The CEO of the Belgian company is Michaël de Blauwe.

PROMETHERA Biosciences SA discovers, develops and commercializes cell therapy products to treat liver diseases. It operates as a pharmaceutical company that develops treatment based on allogeneic adult stem cell technology. The firm’s technology platform is based on a newly discovered cell type, isolated from normal human adult liver tissue: Heterologous Human Adult Liver Progenitor Cells (HHALPC). The company was founded by Etienne Marc Sokal and Eric Halioua on February 12, 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

Amakem NV operates as a biopharmaceutical company. It uses kinase inhibitors for treatments of bowel, eye, and lung diseases. The company was founded by Jack Elands, Dirk Leysen, Olivier Raynald Defert, and Nadya Kaval on July 22, 2009 and is headquartered in Diepenbeek, Belgium.

Life Sciences Research Partners VZW functions as a foundation or endowment. The non-profit company is based in Leuven, Belgium. The Belgian company was founded by Désiré Collen.

Immo David NV engages in the provision real estate rental, sale and purchase services. The company was founded on January 5, 2005 and is headquartered in Asse, Belgium.

Creabuild NV provides consulting services. The private company is based in Zaventem, Belgium. The Belgian company was founded in 2005. The CEO is Stéphane Vandervelde.

Intergem OV is a Belgian electric services company founded in 1980. The company is based in Dendermonde, Belgium. The company provides electric services and is ultimately controlled by the Region of Flanders.

Q-Biologicals NV operates as a bio pharma contract development and manufacturing organization. It provides process development and bio manufacturing services to customers in the biopharmaceutical industry. The company was founded in 2011 and is headquartered in Ghent, Belgium.

iTeos Therapeutics SA engages in the discovery of immunomodulators for cancer therapy. It operates as a biotechnology company which focuses on targeting metabolism of the tumor microenvironment through development of small-molecule immunomodulators for cancer treatment. The firm develops small molecules designed to target the tumor microenvironment by inhibiting cancer-induced immune suppression. Targeting such resistance mechanisms will enhance the clinical efficacy of both standards of care treatments as well as the newer immunomodulatory therapies based on the blockade of immune checkpoints. The company was founded in 2011 by Michel Detheux and Benoit Van den Eynde and is headquartered in Gosselies, Belgium.

MaSTherCell SA engages in providing cell therapy manufacturing services. The company was founded in 2011 and is headquartered in Charleroi, Belgium.

Bioxodes SA develops pharmaceutical products. Its programme Ir-CPI, is the first in a novel class of antithrombotics, and is developed for the prevention of thrombosis in a range of applications including cardiopulmonary bypass grafting and percutaneous coronary intervention. The company was founded by Edmond Godfroid and Michel Guyaux on April 20, 2010 and is headquartered in Marche-en-Famenne, Belgium.

Fund+ is an independent Venture Capital firm founded in 2015. The firm is headquartered in Leuven, Belgium.

EyeD Pharma SA manufactures and supplies ophthalmology surgical products. Its products include R&D, instrumentation and phaco accessories. The company was founded by Jean-Marie Rakic and Jean-Michel Foidart and is headquartered in Liege, Belgium.

Fluvius System Operator CV is based in Melle, Belgium. The Belgian company engages in building, managing, and maintaining the distribution grids for electricity, natural gas, and sewerage systems. Fluvius System Operator CV is a company that was founded in 2002.

Patcobel NV provides real estate services. The private company is based in Kortrijk, Belgium. The CEOs are Cindy van Loock and Patrick Lippens. The Belgian company was founded in 1989.

Cellaïon SA is a biotech company located in Mont Saint Guibert, Belgium. Cellaïon aims to restore a favorable environment to reboost the regenerative process of the liver and ensure a second life to the native liver instead of losing it. The Belgian company has a strong IP base issued from their own research and academic research at UCLouvain, developed with the objective to generate new products. Cellaïon's treatment covers the wide spectrum of liver diseases, from the highly life-threatening acute-on-chronic liver-failure (ACLF) and acute alcoholic hepatitis, to intermediate severity acute decompensation of cirrhosis (AD) and progressive chronic liver diseases caused by non-alcoholic steatohepatitis (NASH). The company has built up a series of R&D and collaborative partnerships with both industrial and academic partners, allowing Cellaïon to broaden and accelerate its clinical development. The company was founded by Etienne Marc Sokal, who has been the CEO since incorporation.